尼塞韦单抗与儿科急诊急性毛细支气管炎发作
该研究回顾性分析西班牙15个儿科急诊2018-2024年流行季数据,比较2023-2024季与前几季平均发病率。结果显示2023-2024季下呼吸道感染、急性毛细支气管炎、相关住院及PICU入住分别下降57.7%、59.2%、63.1%和63.1%,实施扩展补种的地区效果更好。
要点
- 2023-2024季西班牙普遍接种尼塞韦单抗后,儿科急诊下呼吸道感染和急性毛细支气管炎发作显著下降。
- 急性毛细支气管炎相关住院和PICU入住率均下降63.1%,提示重症负担减轻。
- 实施扩展补种(6月龄以下婴儿补种)的地区下降幅度更大,但需考虑成本效益。
核心结论
- 尼塞韦单抗可保护广泛婴儿群体免受呼吸道合胞病毒感染,高效降低急诊就诊和重症住院。
- 包含扩展补种的免疫策略最为有效,但需考虑成本效益。
研究设计与样本
- 比较2018-2023季平均发病率与2023-2024季(引入尼塞韦单抗普遍预防)的下呼吸道感染、急性毛细支气管炎、相关住院及PICU入住情况。
主要发现
- 2023-2024季下呼吸道感染发作较前几季平均下降57.7%(95%CI 56.5-58.8;P<.001;各医院范围4.8-82.8)。
- 急性毛细支气管炎发作下降59.2%(95%CI 57.9-60.4;P<.001;范围6.9-84.1)。
- 急性毛细支气管炎相关住院下降63.1%(95%CI 60.9-65.2;P<.001;范围31.4-86.8)。
- PICU入住下降63.1%(95%CI 58.1-67.9;P<.001;范围18.2-81.8)。
- 实施扩展补种的地区医院结果更好。
临床怎么用
- 在RSV流行季对婴儿普遍使用尼塞韦单抗可显著减少儿科急诊急性毛细支气管炎就诊及重症住院。
- 可考虑对流行季开始时6月龄以下婴儿实施扩展补种以增强保护效果,但需评估成本效益。
局限性
- 本研究为回顾性设计,各医院下降幅度范围较大(如住院下降31.4-86.8),提示存在中心间差异。
- 原文未报告成本效益的具体数据,仅结论中提及需考虑成本效益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: In the 2023-2024 respiratory syncytial virus (RSV) season, Spain became one of the first countries to introduce universal RSV prophylaxis, during which all infants born at this time were eligible to receive nirsevimab. Locally, most Spanish regions also immunized infants younger than age 6 months at the start of the season (extended catch-up). The aim of this study was to assess how RSV prophylaxis affected the number of infants presenting to pediatric emergency departments with acute respiratory infections. METHODS: A retrospective study was conducted in 15 Spanish pediatric emergency departments from 9 different regions between the 2018 and 2024 epidemic seasons (November-January). We compared the seasons occurring in 2018-2023 and the 2023-2024 season regarding the number of episodes of lower respiratory tract infection and acute bronchiolitis, acute bronchiolitis-related hospital admissions, and PICU admissions. RESULTS: A comparison with the average rates for the previous epidemic seasons revealed a 57.7% decrease in episodes of lower respiratory tract infection in 2023-2024 (95% CI, 56.5-58.8; P < .001; range among hospitals, 4.8-82.8), a 59.2% decrease in episodes of acute bronchiolitis (95% CI, 57.9-60.4; P < .001; range, 6.9-84.1), a 63.1% reduction in acute bronchiolitis-related hospital admissions (95% CI, 60.9-65.2; P < .001; range, 31.4-86.8), and a 63.1% reduction in PICU admissions (95% CI, 58.1-67.9; P < .001; range, 18.2-81.8). Hospitals in regions applying extended catch-up showed better results. CONCLUSIONS: Nirsevimab can protect a broad infant population against RSV infection with high effectiveness. Approaches including extended catch-up are the most effective, although cost- effectiveness must be considered.
引用
- Andina Martínez D, Claret Teruel G, Gijón Mediavilla M, et al. Nirsevimab and Acute Bronchiolitis Episodes in Pediatric Emergency Departments. Pediatrics. 2024. PMID: 39257372. doi:10.1542/peds.2024-066584
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。